OnKure Therapeutics (OKUR) Common Equity (2020 - 2026)

OnKure Therapeutics (OKUR) has reported Common Equity for 7 consecutive years, with $172.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 120.18% year-over-year to $172.1 million; the trailing twelve-month figure through Jun 2026 stood at $172.1 million (up 120.18% YoY), and the FY2025 full-year result was $56.2 million, down 45.89% from the prior year.
• Common Equity fell to $172.1 million in Q2 2026 per OKUR's latest filing, from $184.4 million in the prior quarter.
• Across five years, Common Equity topped out at $184.4 million in Q1 2026 and bottomed at -$135.0 million in Q3 2024.
• Historically, Common Equity has averaged $51.8 million across 5 years, with a median of $88.9 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Common Equity surged 377.76% in 2022, then slumped 227.76% in 2024.
• Over 5 years, Common Equity stood at -$54.4 million in 2022, then slumped by 87.15% to -$101.8 million in 2023, then surged by 201.95% to $103.8 million in 2024, then plunged by 45.89% to $56.2 million in 2025, then surged by 206.33% to $172.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $172.1 million, $184.4 million, and $56.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.